| Date | Title | Description |
| 07.08.2025 | Notice to Extraordinary General Meeting in Hansa Biopharma AB (publ) | Notice to Extraordinary General Meeting in Hansa Biopharma AB (publ)
Thu, Aug 07, 2025 07:00 CET Report this content
Lund, Sweden August 7, 2025, Hansa Biopharma AB (publ), Reg. No. 556734-5359 (“Hansa Biopharma”), with registered office in... |
| 25.07.2025 | Phavaris secures over $200 million to advance clinical developments |
Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioed... |
| 25.07.2025 | Pharvaris secures over $200 million to advance clinical developments |
Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioed... |
| 10.04.2024 | Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | RAPIDe-3, a global pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, is currently enrolling
End-of-Phase 2 meeting scheduled to discuss development plan of deucrictibant for the prophylaxis of HAE attacks
St... |
| 06.03.2024 | Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses | - |
| 05.03.2024 | Pharvaris to Participate in the Leerink Global Biopharma Conference 2024 | - |
| 05.01.2024 | Pharvaris Provides Business Update and Outlines 2024 Strategic Priorities | RAPIDe-3, a global Phase 3 clinical study of deucrictibant for the on-demand treatment of HAE, to initiate within 1H24
Results of nonclinical rodent toxicology study submitted to the FDA
Jochen Knolle, Ph.D., to transition to strategic advi... |
| 06.12.2023 | Pharvaris Announces Pricing of $300 Million Underwritten Offering of Ordinary Shares and Pre-funded Warrants | - |
| 06.12.2023 | Why Cerevel Therapeutics has risen 50% in three days without changing anything | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hello, everyone. Damian here with some unrest at well-funded startups, a curious biotech run-up, and long-awaited ne... |
| 06.12.2023 | Leadership changes with some promotions | |
| 21.07.2023 | Pharvaris Presents Clinical Data at the 2023 U.S. HAEA National Summit | /EIN News/ -- ZUG, Switzerland, July 21, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today s... |
| 26.06.2023 | Pharvaris obtains $70 million in a private placement round | |
| 20.06.2023 | Pharvaris Announces $70 Million Private Placement Financing | - |
| 10.06.2023 | Data of Deucrictibant for the On-Demand Treatment of HAE Attacks Presented at the EAACI Congress 2023 | Posters highlight clinically meaningful improvement in HAE symptoms observed in the first hours after treatment with PHVS416 (deucrictibant immediate-release capsules) as compared to placebo
/EIN News/ -- ZUG, Switzerland, June 11, 2023 (GL... |
| 05.04.2023 | Pharvaris Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update | Top-line data from CHAPTER-1, a proof-of-concept Phase 2 study of PHVS416 for the prophylactic treatment of HAE, anticipated in 2H2023
26-week non-clinical toxicology study intended to address the clinical holds in the U.S. initiated; submi... |
| 24.08.2022 | Swiss biotechs in dispute with regulators | |
| 22.12.2021 | Pharvaris N : Announces Changes to its Board of Directors - Form 6-K | Pharvaris Announces Changes to its Board of Directors
Zug, Switzerland, Dec. 22, 2021 - Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for... |
| 22.12.2021 | Pharvaris Announces Changes to its Board of Directors | ZUG, Switzerland, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioed... |
| 07.12.2021 | Pharvaris N : Announces Changes to its Board of Directors - Form 6-K | Pharvaris Announces Changes to its Board of Directors
Zug, Switzerland, December 7, 2021 - Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists ... |
| 07.12.2021 | Pharvaris Announces Changes to its Board of Directors | ZUG, Switzerland, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioed... |
| 10.11.2021 | Pharvaris Reports Third Quarter 2021 Financial Results and Provides Business Highlights | RAPIDe-1, Phase 2 on-demand study of PHVS416 for the treatment of HAE attacks, proceeding; topline data reaffirmed for 2022
CHAPTER-1, Phase 2 prophylactic study of PHVS416 for the prevention of HAE attacks, recruiting; topline data expecte... |
| 10.11.2021 | Pharvaris Reports Third Quarter 2021 Financial Results and Provides Business Highlights - Form 6-K | Pharvaris Reports Third Quarter 2021 Financial Results and Provides Business Highlights
• RAPIDe-1, Phase 2 on-demand study of PHVS416 for the treatment of HAE attacks, proceeding; topline data reaffirmed for 2022
• CHAPTER-1, Phase 2 proph... |
| 30.07.2021 | Pharvaris N : Reports Second Quarter 2021 Financial Results and Provides Business Highlights (Form 6-K) | Pharvaris Reports Second Quarter 2021 Financial Results and Provides Business Highlights
• RAPIDe-1, Phase 2 on-demand study of PHVS416 for the treatment of HAE attacks expanding to US, expected to report data in 2022
• CHAPTER-1, Phase 2 p... |
| 10.07.2021 | Pharvaris N : Presents Clinical Data on Oral PHA121 Supporting the Prophylactic Treatment of Hereditary Angioedema at the EAACI Annual Congress 2021 | ZUG, Switzerland, July 10, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioed... |
| 01.07.2021 | Pharvaris N : to Present PHA121 Clinical Data for Oral Treatment of Hereditary Angioedema at the EAACI Annual Congress 2021 (Form 6-K) | Pharvaris to Present PHA121 Clinical Data for Oral Treatment of Hereditary Angioedema at the EAACI Annual Congress 2021
Zug, Switzerland, July 1, 2021 - Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and comme... |
| 11.06.2021 | PHARVARIS N.V.
Pharvaris N : Announces Annual Meeting of Shareholders (Form 6-K) | Pharvaris Announces Annual Meeting of Shareholders
Zug, Switzerland, June 11, 2021 - Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for th... |
| 28.05.2021 | BRAIN BIOTECH AG
BRAIN Biotech : Präsentation Analysten Call 6M GJ 2020/21 (englisch) | BRAIN Biotech AG
Creating a #BiobasedFuture
Analyst Call 6M, FY 2020/'21
Adriaan Moelker, CEO
Lukas Linnig, CFO
Zwingenberg, May 28th, 2021
Creating a #BiobasedFuture © BRAIN Biotech AG Zwingenberg Germany www.brain-biotech.com +49 (0) 6251... |
| 26.05.2021 | PHARVARIS N.V.
Pharvaris N : Reports First Quarter 2021 Financial Results and Provides Business Highlights | RAPIDe-1, Phase 2 on-demand study of PHVS416 for the treatment of HAE attacks proceeding
HAE CHAPTER-1, Phase 2 prophylactic study of PHVS416 for prevention of HAE attacks, on-track to initiate in 2021
Viviane Monges nominated to Board of D... |
| 26.05.2021 | PHARVARIS N.V.
Pharvaris N : Reports First Quarter 2021 Financial Results and Provides Business Highlights (Form 6-K) | Pharvaris Reports First Quarter 2021 Financial Results and Provides Business Highlights
• RAPIDe-1, Phase 2 on-demand study of PHVS416 for the treatment of HAE attacks proceeding
• HAE CHAPTER-1, Phase 2 prophylactic study of PHVS416 for pr... |
| 14.05.2021 | PHARVARIS N.V.
Pharvaris N : Appoints Wim Souverijns, Ph.D., as Chief Community Engagement & Commercial Officer (Form 6-K) | Pharvaris Appoints Wim Souverijns, Ph.D., as
Chief Community Engagement & Commercial Officer
• Industry veteran with deep commercial experience further strengthens leadership team as company advances development of multiple oral product... |
| 12.05.2021 | PHARVARIS B.V.
Pharvaris B : Appoints Wim Souverijns, Ph.D., as Chief Community Engagement & Commercial Officer | Industry veteran with deep commercial experience further strengthens leadership team as company advances development of multiple oral products for HAE patients
ZUG, Switzerland, May 12, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a c... |
| 03.05.2021 | PHARVARIS B.V.
Pharvaris B : Amendment to Current Report by Foreign Issuer (SEC Filing - 6-K/A) | Exhibit 99.1
Pharvaris Reports Full Year 2020 Financial Results and Provides Business Highlights
• RAPIDe-1 clinical trial enrolling, evaluating PHVS416 as an oral on-demand therapy for HAE
• Open IND for the prophylactic evaluation of PHVS... |
| 30.04.2021 | PHARVARIS B.V.
Pharvaris B : Reports Full Year 2020 Financial Results and Provides Business Highlights | Pharvaris Reports Full Year 2020 Financial Results and Provides Business Highlights
• RAPIDe-1 clinical trial enrolling, evaluating PHVS416 as an oral on-demand therapy for HAE
• Open IND for the prophylactic evaluation of PHVS416
• Strong ... |
| 21.04.2021 | PHARVARIS B.V.
Pharvaris B : Announces FDA Acceptance of IND Application for Prophylactic Treatment of HAE Using PHVS416 | ZUG, Switzerland, April 21, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HA... |
| 28.02.2021 | 3 New IPOs Trending Higher Heading Into March | February was an active month for IPOs. |
| 05.02.2021 | Pharvaris goes public and raises $165 million | Last November, Pharvaris has closed an oversubscribed $80 million Series C financing bringing its total venture funding to over $160 million to date. The company is now going public at Nasdaq. Prospects look promising. During the week the c... |
| 05.02.2021 | Pharvaris goes public and raises $165 million | |
| 27.01.2021 | Pharvaris Announces Phase 1 Clinical Data of PHA121, an Oral B2 Receptor Antagonist Under Development for the Treatment of Hereditary Angioedema | |
| 05.01.2021 | Pharvaris Expands Board of Directors with Appointment of David Meeker, M.D., as Chair and Robert Glassman, M.D., as Director | |
| 19.11.2020 | Pharvaris Announces $80 Million Series C Financing | |
| 19.11.2020 | Pharvaris Announces $80 Million Series C Financing | Hereditary angioedema (HAE) is a rare and potentially life-threatening genetic condition with symptoms that include episodes of debilitating and often painful swelling in the hands, feet, face (lips and tongue), gastrointestinal tract, urog... |
| 18.11.2020 | Pharvaris B.V. announced that it has received $80 million in funding from a group of investors | Pharvaris B.V. announced that it has received $80 million in a round of funding co-led by new investors, Viking Global Investors LP and General Atlantic Service Company, L.P. on November 18, 2020. The transaction also included participation... |
| 18.11.2020 | Pharvaris lands another $80M as it looks to tackle Takeda and CSL with an oral approach for HAE | A year after their $66 million launch, the Swiss upstart Pharvaris has managed to convince another fleet of new and returning investors to back their upstart approach for a rare genetic condition called hereditary angioe... |
| 18.11.2020 | Pharvaris Raises $80M in Series C Financing | Pharvaris, a Zug, Switzerland-based clinical-stage company, closed an $80m Series C financing bringing its total venture funding to over $160m to date.
The round was co-led by Viking Global Investors and General Atlantic, with participation... |
| 18.11.2020 | Pharvaris Announces $80 Million Series C Financing to Advance Novel Oral Bradykinin-B2-Receptor Antagonists for the Treatment of HAE | |
